Andrew D. Seidman, MD, and Meredith M. Regan, ScD, on Breast Cancer: Results From the TEXT and SOFT Trials
2018 ASCO Annual Meeting
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, discuss study findings on absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor–positive, HER2-negative breast cancer (Abstract 503).
Apostolia-Maria Tsimberidou, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses findings on clinical outcomes, including long-term survival, according to the pathway targeted and treatment period (Abstract LBA2553).
Peter Hillmen, MB, ChB, of St James’s University Hospital, discusses phase III study findings on minimal residual disease negativity with venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia (Abstract 7508).
Michael Gnant, MD, of the Medical University of Vienna, discusses study findings on adjuvant denosumab in early breast cancer––a disease-free survival analysis of postmenopausal patients.
Supriya G. Mohile, MD, of the University of Rochester Medical Center, discusses study findings on ways to improve communication with older cancer patients using geriatric assessment (Abstract LBA10003).
Jeremy S. Abramson, MD, of the Massachusetts General Hospital, discusses study findings on lisocabtagene maraleucel in relapsed or refractory aggressive NHL (Abstract 7505).
